<p>印第安納波利斯 --（商業資訊）--Elevance Health, Inc.（紐約證券交易所代碼：ELV）今天宣佈了一系列管理變動，旨在簡化決策過程並加強 Carelon 和健康福利的執行力。</p>
<p>作為這些變動的一部分，執行副總裁兼首席財務官 Mark Kaye 將擴大其職責，負責監督 Carelon，該公司提供包括藥房服務、行為健康、基於價值的護理和護理交付能力在內的醫療服務運營。Carelon 在推動公司降低護理成本的戰略中發揮着關鍵作用。Carelon 的運營優先事項和客户承諾保持不變。</p>
<p>執行副總裁兼首席健康福利官 Felicia Norwood 將負責公司的綜合健康福利組織，將公司的主要健康福利業務和核心運營職能整合到一個可問責的結構下。這一整合增強了商業和政府健康福利之間的協調，並支持產品、運營和增長優先事項之間更一致的運營節奏。</p>
<p>Peter D. Haytaian 已宣佈，他將於 2026 年 5 月 4 日起從執行副總裁兼 Carelon 總裁的職位上過渡，以便投入更多時間於家庭事務。Haytaian 將擔任公司的特別顧問，直至 2026 年 12 月 31 日，以支持有序的領導過渡，並確保 Carelon 的運營及客户和合作夥伴關係的連續性。</p>
<p>“在過去的幾年裏，我們不斷演變我們的運營方式，以滿足醫療保健的變化需求，併為我們的客户、會員和合作夥伴提供服務，” Elevance Health 的總裁兼首席執行官 Gail Boudreaux 表示。“這些管理變動支持有序的執行，並幫助我們在繼續擴展的過程中以更清晰和協調的方式行動。我還要感謝 Pete 的領導和他對支持順利過渡的承諾。”</p>
<p>“我期待領導 Carelon 團隊，基於我們堅實的基礎，為客户和合作夥伴提供服務，並以支持可持續增長和長期價值的紀律性執行，” Kaye 説道。</p>
<p>Norwood 補充道：“將健康福利整合到一個可問責的結構下，增強了協調和執行力，使我們能夠繼續為會員和客户提供服務。”</p>
<p><strong>關於 Elevance Health</strong></p>
<p>Elevance Health 是一個終身值得信賴的健康合作伙伴，其宗旨是改善人類健康。該公司支持消費者、家庭和社區在整個醫療保健旅程中，幫助他們連接到所需的護理、支持和資源，以過上更好的生活。Elevance Health 的公司通過多樣化的行業領先醫療、藥房、行為、臨牀、家庭健康和複雜護理解決方案，服務約 1.04 億消費者。欲瞭解更多信息，請訪問 www.elevancehealth.com 或在 X 上關注我們 @ElevanceHealth，在 LinkedIn 上關注 Elevance Health。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本文件包含 1995 年《私人證券訴訟改革法案》所定義的某些前瞻性陳述。前瞻性陳述反映了我們對未來事件和財務表現的看法，通常不是歷史事實。諸如 “期望”、“感覺”、“相信”、“將”、“可能”、“應該”、“預期”、“打算”、“估計”、“項目”、“預測”、“計劃”、“潛在”、“預測” 等詞語旨在識別前瞻性陳述。這些陳述包括但不限於：財務預測和估計及其基本假設；關於未來運營、產品和服務的計劃、目標和期望的陳述；以及關於未來表現的陳述。這些陳述受到某些風險和不確定性的影響，其中許多是難以預測的，通常超出我們的控制範圍，可能導致實際結果與前瞻性陳述中表達、暗示或預測的結果有重大差異。請注意，不要對這些僅在本日期時有效的前瞻性陳述過於依賴。我們還敦促您仔細審查和考慮我們不時向美國證券交易委員會提交的報告中討論的各種風險和其他披露，這些報告試圖告知相關方影響我們業務的因素。除法律要求外，我們不會更新或修訂任何前瞻性陳述，以反映本日期後發生的事件或情況。這些風險和不確定性包括但不限於：醫療成本和利用率的趨勢；註冊人數減少；我們確保和實施足夠保費率的能力；大規模醫療緊急情況的影響，例如公共衞生流行病和其他災難；新法律或現有聯邦、州和國際法律或法規的變化及其影響，包括影響醫療、保險、藥房服務和其他多元化產品和服務的法律法規，或其執行或適用；網絡攻擊或其他隱私或數據安全事件的影響，或我們未能遵守任何隱私、數據或安全法律法規，包括與此相關的任何調查、索賠或訴訟；未能有效維護和現代化我們的信息系統；我們的信息系統或技術（包括人工智能）未能按預期運行；未能有效維護我們數據的可用性和完整性；經濟和市場條件的變化，以及可能對我們的流動性和投資組合產生負面影響的法規；競爭壓力以及我們適應行業變化和開發、實施戰略增長機會的能力；關於醫療保險和醫療補助計劃的風險和不確定性，包括與複雜法規不合規相關的風險；我們在醫療保險和醫療補助服務中心的星級評分和其他質量評分的維持和改善能力，以及與參與其中所獲得收入相關的資金風險；我們醫療產品組合的負面變化；與訴訟、政府調查、審計或審查相關的成本和其他責任；我們與提供者以具有成本效益和競爭力的條款簽訂合同的能力；提供醫療、藥房和其他多元化產品和服務的風險，包括醫療事故或專業責任索賠，以及任何一方未能遵守我們與 CaremarkPCS Health, L.L.C.之間的藥房服務協議；與健康福利行業或我們本身相關的任何負面宣傳或情緒的影響；與併購、合資企業和戰略聯盟相關的風險；如果未來結果未能充分支持商譽和其他無形資產，可能導致我們無形資產價值的減值；從我們的子公司支付股息的可能限制以及對最低資本水平的要求增加；由於現金流和收益的充足性及其他考慮，我們回購普通股和支付普通股股息的能力；我們大量未償債務可能產生的潛在負面影響，以及利率上升或市場波動可能影響我們融資的獲取或進一步增加融資成本的風險；我們財務實力評級的下調；可能對我們與藍十字藍盾協會的許可證產生負面影響的事件；吸引和留住員工的激烈競爭；與我們國際業務相關的風險；以及我們治理文件中的各種法律和條款，可能阻止或阻礙收購和商業合併。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMjYyMTc3NDFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMjYyMTc3NDFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260226217741/en/</p>
<p>Elevance Health 聯繫人：</p>
<p><strong>投資者關係：</strong></p>
<p>Nathan Rich</p>
<p>Investor.Relations@elevancehealth.com</p>
<p><strong>媒體聯繫人：</strong></p>
<p>Leslie Porras</p>
<p>Leslie.Porras@elevancehealth.com</p>
<p>來源：Elevance Health, Inc.</p>

美國醫療保健供應商 ETF - iShares

醫療業 ETF - Vanguard

醫療業 ETF - SPDR

<p>Elevance Health, Inc. 宣佈管理層變動，以增強其 Carelon 和健康福利部門的決策和執行能力。首席財務官 Mark Kaye 現在將負責 Carelon，而 Felicia Norwood 將領導整合後的健康福利組織。Peter D. Haytaian 將從 Carelon 總裁的職位轉任特別顧問。這些變動旨在改善協調，支持公司的可持續增長</p>

<p>INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits.</p>
<div class="lb-trans"><p>印第安納波利斯 --（商業資訊）--Elevance Health, Inc.（紐約證券交易所代碼：ELV）今天宣佈了一系列管理變動，旨在簡化決策過程並加強 Carelon 和健康福利的執行力。</p>
</div><p>As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company’s healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company’s strategy to lower the cost of care. Carelon’s operating priorities and client commitments remain unchanged.</p>
<div class="lb-trans"><p>作為這些變動的一部分，執行副總裁兼首席財務官 Mark Kaye 將擴大其職責，負責監督 Carelon，該公司提供包括藥房服務、行為健康、基於價值的護理和護理交付能力在內的醫療服務運營。Carelon 在推動公司降低護理成本的戰略中發揮着關鍵作用。Carelon 的運營優先事項和客户承諾保持不變。</p>
</div><p>Felicia Norwood, Executive Vice President and Chief Health Benefits Officer, will assume responsibility for the Company’s consolidated Health Benefits organization, bringing together the Company’s major Health Benefits businesses and core operating functions under a single accountable structure. This consolidation enhances coordination across Commercial and Government health benefits and supports a more consistent operating cadence across product, operations, and growth priorities.</p>
<div class="lb-trans"><p>執行副總裁兼首席健康福利官 Felicia Norwood 將負責公司的綜合健康福利組織，將公司的主要健康福利業務和核心運營職能整合到一個可問責的結構下。這一整合增強了商業和政府健康福利之間的協調，並支持產品、運營和增長優先事項之間更一致的運營節奏。</p>
</div><p>Peter D. Haytaian has announced that he will transition from his role as Executive Vice President and President of Carelon effective May 4, 2026, in order to devote more time to family commitments. Haytaian will serve the Company as Special Advisor through December 31, 2026, to support an orderly leadership transition and ensure continuity across Carelon’s operations and client and partner relationships.</p>
<div class="lb-trans"><p>Peter D. Haytaian 已宣佈，他將於 2026 年 5 月 4 日起從執行副總裁兼 Carelon 總裁的職位上過渡，以便投入更多時間於家庭事務。Haytaian 將擔任公司的特別顧問，直至 2026 年 12 月 31 日，以支持有序的領導過渡，並確保 Carelon 的運營及客户和合作夥伴關係的連續性。</p>
</div><p>“Over the last several years, we have continued to evolve how we operate to meet the changing needs of healthcare and deliver for our customers, members, and clients,” said Gail Boudreaux, President and Chief Executive Officer of Elevance Health. “These management changes support disciplined execution and help us move with greater clarity and coordination as we continue to scale. I also want to thank Pete for his leadership and his commitment to supporting a smooth transition.”</p>
<div class="lb-trans"><p>“在過去的幾年裏，我們不斷演變我們的運營方式，以滿足醫療保健的變化需求，併為我們的客户、會員和合作夥伴提供服務，” Elevance Health 的總裁兼首席執行官 Gail Boudreaux 表示。“這些管理變動支持有序的執行，並幫助我們在繼續擴展的過程中以更清晰和協調的方式行動。我還要感謝 Pete 的領導和他對支持順利過渡的承諾。”</p>
</div><p>“I look forward to leading the Carelon team as we build on our strong foundation, deliver for clients and partners, and execute with discipline that supports sustainable growth and long-term value,” said Kaye.</p>
<div class="lb-trans"><p>“我期待領導 Carelon 團隊，基於我們堅實的基礎，為客户和合作夥伴提供服務，並以支持可持續增長和長期價值的紀律性執行，” Kaye 説道。</p>
</div><p>Norwood added, “Bringing Health Benefits together under a single accountable structure strengthens coordination and execution as we continue delivering for members and customers.”</p>
<div class="lb-trans"><p>Norwood 補充道：“將健康福利整合到一個可問責的結構下，增強了協調和執行力，使我們能夠繼續為會員和客户提供服務。”</p>
</div><p><strong>About Elevance Health</strong></p>
<div class="lb-trans"><p><strong>關於 Elevance Health</strong></p>
</div><p>Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 104 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.</p>
<div class="lb-trans"><p>Elevance Health 是一個終身值得信賴的健康合作伙伴，其宗旨是改善人類健康。該公司支持消費者、家庭和社區在整個醫療保健旅程中，幫助他們連接到所需的護理、支持和資源，以過上更好的生活。Elevance Health 的公司通過多樣化的行業領先醫療、藥房、行為、臨牀、家庭健康和複雜護理解決方案，服務約 1.04 億消費者。欲瞭解更多信息，請訪問 www.elevancehealth.com 或在 X 上關注我們 @ElevanceHealth，在 LinkedIn 上關注 Elevance Health。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p><em>This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems; failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.</em></p>
<div class="lb-trans"><p>本文件包含 1995 年《私人證券訴訟改革法案》所定義的某些前瞻性陳述。前瞻性陳述反映了我們對未來事件和財務表現的看法，通常不是歷史事實。諸如 “期望”、“感覺”、“相信”、“將”、“可能”、“應該”、“預期”、“打算”、“估計”、“項目”、“預測”、“計劃”、“潛在”、“預測” 等詞語旨在識別前瞻性陳述。這些陳述包括但不限於：財務預測和估計及其基本假設；關於未來運營、產品和服務的計劃、目標和期望的陳述；以及關於未來表現的陳述。這些陳述受到某些風險和不確定性的影響，其中許多是難以預測的，通常超出我們的控制範圍，可能導致實際結果與前瞻性陳述中表達、暗示或預測的結果有重大差異。請注意，不要對這些僅在本日期時有效的前瞻性陳述過於依賴。我們還敦促您仔細審查和考慮我們不時向美國證券交易委員會提交的報告中討論的各種風險和其他披露，這些報告試圖告知相關方影響我們業務的因素。除法律要求外，我們不會更新或修訂任何前瞻性陳述，以反映本日期後發生的事件或情況。這些風險和不確定性包括但不限於：醫療成本和利用率的趨勢；註冊人數減少；我們確保和實施足夠保費率的能力；大規模醫療緊急情況的影響，例如公共衞生流行病和其他災難；新法律或現有聯邦、州和國際法律或法規的變化及其影響，包括影響醫療、保險、藥房服務和其他多元化產品和服務的法律法規，或其執行或適用；網絡攻擊或其他隱私或數據安全事件的影響，或我們未能遵守任何隱私、數據或安全法律法規，包括與此相關的任何調查、索賠或訴訟；未能有效維護和現代化我們的信息系統；我們的信息系統或技術（包括人工智能）未能按預期運行；未能有效維護我們數據的可用性和完整性；經濟和市場條件的變化，以及可能對我們的流動性和投資組合產生負面影響的法規；競爭壓力以及我們適應行業變化和開發、實施戰略增長機會的能力；關於醫療保險和醫療補助計劃的風險和不確定性，包括與複雜法規不合規相關的風險；我們在醫療保險和醫療補助服務中心的星級評分和其他質量評分的維持和改善能力，以及與參與其中所獲得收入相關的資金風險；我們醫療產品組合的負面變化；與訴訟、政府調查、審計或審查相關的成本和其他責任；我們與提供者以具有成本效益和競爭力的條款簽訂合同的能力；提供醫療、藥房和其他多元化產品和服務的風險，包括醫療事故或專業責任索賠，以及任何一方未能遵守我們與 CaremarkPCS Health, L.L.C.之間的藥房服務協議；與健康福利行業或我們本身相關的任何負面宣傳或情緒的影響；與併購、合資企業和戰略聯盟相關的風險；如果未來結果未能充分支持商譽和其他無形資產，可能導致我們無形資產價值的減值；從我們的子公司支付股息的可能限制以及對最低資本水平的要求增加；由於現金流和收益的充足性及其他考慮，我們回購普通股和支付普通股股息的能力；我們大量未償債務可能產生的潛在負面影響，以及利率上升或市場波動可能影響我們融資的獲取或進一步增加融資成本的風險；我們財務實力評級的下調；可能對我們與藍十字藍盾協會的許可證產生負面影響的事件；吸引和留住員工的激烈競爭；與我們國際業務相關的風險；以及我們治理文件中的各種法律和條款，可能阻止或阻礙收購和商業合併。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMjYyMTc3NDFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260226217741r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260226217741/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260226217741/en/</p>
</div><p>Elevance Health Contacts:</p>
<div class="lb-trans"><p>Elevance Health 聯繫人：</p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投資者關係：</strong></p>
</div><p>Nathan Rich</p>
<div class="lb-trans"><p>Nathan Rich</p>
</div><p>Investor.Relations@elevancehealth.com</p>
<div class="lb-trans"><p>Investor.Relations@elevancehealth.com</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫人：</strong></p>
</div><p>Leslie Porras</p>
<div class="lb-trans"><p>Leslie Porras</p>
</div><p>Leslie.Porras@elevancehealth.com</p>
<div class="lb-trans"><p>Leslie.Porras@elevancehealth.com</p>
</div><p>Source: Elevance Health, Inc.</p>
<div class="lb-trans"><p>來源：Elevance Health, Inc.</p>
</div>

Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization | ELV Stock News

Elevance Health 宣佈管理層變動：首席財務官 Mark Kaye 將擴大職責範圍，涵蓋 Carelon，Felicia Norwood 將負責領導合併後的健康福利組織 | ELV 股票新聞